Long-term outcomes of elderly patients with CYP2C9 and VKORC1 variants treated with vitamin K antagonists (original) (raw)
Haemorrhagic Complications of Vitamin K Antagonists in the Elderly
Pascale GAUSSEM
Drugs & Aging, 2006
View PDFchevron_right
Effects of CYP2C9 and VKORC1 on INR variations and dose requirements during initial phase of anticoagulant therapy
Lidia Rota
Pharmacogenomics, 2008
View PDFchevron_right
The predictive ability of bleeding risk stratification models in very old patients on vitamin K antagonist treatment for venous thromboembolism: results of the prospective collaborative EPICA study
Emilia Antonucci
Journal of Thrombosis and Haemostasis, 2013
View PDFchevron_right
The predictive ability of bleeding risk stratification models in very old patients on vitamin K antagonist treatment for venous thromboembolism: results of the prospective collaborative EPICA study: comment
Yoann Gaboreau
Journal of Thrombosis and Haemostasis, 2014
View PDFchevron_right
A new vitamin K epoxide reductase complex subunit-1 (VKORC1) mutation in a patient with decreased stability of CYP2C9 enzyme
Arturo Cafolla
Journal of Thrombosis and Haemostasis, 2007
View PDFchevron_right
Effects on bleeding complications of pharmacogenetic testing for initial dosing of vitamin K antagonists: a systematic review and meta-analysis
M. Cruciani
View PDFchevron_right
Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy
Joyce Goldstein
Blood Cells, Molecules, and Diseases, 2009
View PDFchevron_right
The Bleeding Risk during Warfarin Therapy Is Associated with the Number of Variant Alleles of CYP2C9 and VKORC1 Genes
Petr Goetz, Václav Maťoška, Martin Bojar, Martin Šrámek, Ales Tomek
Cardiology, 2013
View PDFchevron_right
Extremely low therapeutic doses of acenocoumarol in a patient with CYP2C9*3/*3 and VKORC1-1639A/A genotype
ANTIGONI CHAIDAROGLOU
Pharmacogenomics, 2019
View PDFchevron_right
Influence of CYP2C9 and VKORC1 on Patient Response to Warfarin: A Systematic Review and Meta-Analysis
Munir Pirmohamed
PLoS ONE, 2012
View PDFchevron_right
Platelet Count and Major Bleeding in Patients Receiving Vitamin K Antagonists for Acute Venous Thromboembolism, Findings From Real World Clinical Practice
maria del valle Morales
Medicine, 2015
View PDFchevron_right
Frequency Distribution of CYP2C9 and VKORC1 Mutations among Bulgarian Patients and their Importance for Anticoagulant Therapy
Julieta Hristova, Valentin Nikolov, Milena Velizarova, Philip Abedinov
2022
View PDFchevron_right
CYP2C9, VKORC1, CYP4F2, ABCB1 and F5 variants: Influence on quality of long-term anticoagulation
Renu Saxena
Pharmacological Reports, 2014
View PDFchevron_right
Vascular Health and Risk Management Adverse drug events associated with vitamin K antagonists: factors of therapeutic imbalance
Pascale Salameh
View PDFchevron_right
Frequency of vitamin K oxidoreductase complex subunit-1 (VKORC1) polymorphisms and warfarin dose management in patients with venous thromboembolism
Nalan Demir
The pharmacogenomics journal, 2018
View PDFchevron_right
Association between genetic polymorphisms of CYP2C9 and VKORC1 and safety and efficacy of warfarin: Results of a 5 years audit
Mansij Biswas
Indian Heart Journal, 2018
View PDFchevron_right
pharmacogenetics implementation consortium guidelines for cyp2c9 and vkorc1 genotypes and warfarin dosing. Clin Pharmacol Ther
M. Wadelius
2020
View PDFchevron_right
Opposite Response to Vitamin K Antagonists: A Report of Two Cases and Systematic Review of Literature
Valentina Manzo
Journal of Personalized Medicine
View PDFchevron_right
The Pharmacology and Management of the Vitamin K Antagonists
Gualtiero Palareti
CHEST Journal, 2004
View PDFchevron_right
Long‐term anticoagulant effects of CYP2C9 and VKORC1 genotypes in phenprocoumon users
Loes Visser
Journal of Thrombosis and Haemostasis, 2012
View PDFchevron_right
Impact of glomerular filtration estimate on bleeding risk in very old patients treated with vitamin K antagonists
Emilia Antonucci
Thrombosis and Haemostasis, 2012
View PDFchevron_right
Dietary vitamin K intake and anticoagulation in elderly patients
Michelli de Assis
Current Opinion in Internal Medicine, 2007
View PDFchevron_right